Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fanconi's anemia and malignancies

B P Alter1

  • 1Division of Pediatric Hematology/Oncology, University of Texas Medical Branch, Galveston 77555-0361, USA.

American Journal of Hematology
|October 1, 1996
PubMed
Summary

Patients with Fanconi

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

VACTERL-H Association and Fanconi Anemia.

Molecular syndromology·2013
Same author

Disease-specific hematopoietic cell transplantation: nonmyeloablative conditioning regimen for dyskeratosis congenita.

Bone marrow transplantation·2010
Same author

Oral and dental phenotype of dyskeratosis congenita.

Oral diseases·2008
Same author

Griscelli syndrome: rare neonatal syndrome of recurrent hemophagocytosis.

Journal of pediatric hematology/oncology·2002
Same author

Modern review of congenital hypoplastic anemia.

Journal of pediatric hematology/oncology·2001
Same author

Comparative genome analysis delimits a chromosomal domain and identifies key regulatory elements in the alpha globin cluster.

Human molecular genetics·2001

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Fanconi's anemia (FA) patients face elevated risks for various cancers.
  • Leukemia is a known complication (approx. 10%), with risk increasing with age.
  • Myelodysplastic syndromes (approx. 5%) and solid tumors are also significant concerns.

Purpose of the Study:

  • To identify and emphasize the spectrum of tumors associated with Fanconi's anemia.
  • To highlight the increasing risk of solid tumors in aging FA patients.
  • To inform hematologists about the broader oncological risks beyond leukemia.

Main Methods:

  • Review of existing literature and clinical data on Fanconi's anemia and associated malignancies.
  • Analysis of reported cancer types, frequencies, and demographic ratios in FA patients.
  • Identification of potential contributing factors, including treatments and age.

Main Results:

  • Leukemia occurs in about 10% of FA patients; myelodysplastic syndromes in about 5%.
  • Solid tumors are increasingly recognized, affecting at least 5% of patients (liver tumors, other cancers).
  • Specific gender ratios are noted for different tumor types, suggesting distinct risk factors.

Conclusions:

  • Fanconi's anemia patients are at high risk for both hematologic and solid tumors.
  • The incidence of solid tumors is expected to rise as FA patients live longer.
  • Comprehensive surveillance for a wide range of malignancies is crucial for Fanconi's anemia care.

Related Experiment Videos